ABL Bio Past Earnings Performance

Past criteria checks 0/6

ABL Bio's earnings have been declining at an average annual rate of -45.7%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 1.7% per year.

Key information

-45.7%

Earnings growth rate

-44.7%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-1.7%
Return on equity-27.1%
Net Margin-151.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Nov 20
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

May 29
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

Feb 26
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Mar 31
We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Jan 20
Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Dec 16
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Revenue & Expenses Breakdown

How ABL Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A298380 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2432,321-49,04116,16764,092
30 Jun 2432,955-40,00315,52655,789
31 Mar 2433,103-38,95215,07355,391
31 Dec 2365,547-2,64713,49352,035
30 Sep 2367,446-7,95114,66153,845
30 Jun 2397,25423,60814,27553,925
31 Mar 23104,80336,10114,71952,347
31 Dec 2267,3013,20915,56948,416
30 Sep 2257,9944,35214,37945,801
31 Dec 215,332-43,55813,27941,034

Quality Earnings: A298380 is currently unprofitable.

Growing Profit Margin: A298380 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A298380's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare A298380's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A298380 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A298380 has a negative Return on Equity (-27.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ABL Bio Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Haesoon KwonEugene Investment & Securities Co Ltd.
Jihoon ShinLS Securities Co., Ltd.